Document 0726
 DOCN  M94A0726
 TI    PCR analysis for common HIV-1 zidovudine resistance mutations in pol DNA
       of untreated and zidovudine treated patients.
 DT    9412
 AU    Salem H; Nightingale B; Garsia RJ; Molecular Biology Department, Royal
       Prince Alfred Hospital,; Camperdown, NSW.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:109 (poster no. 69).
       Unique Identifier : AIDSLINE ASHM5/94348929
 AB    METHODS: Mutations of the HIV-1 pol gene, causing amino acid changes at
       codons 41, 67, 70, 215 and 219, were sought in DNA of serial HIV-1
       infected patients. Exposure to Zidovudine (ZDV) was nil in 12 cases and
       ranged from < 4 weeks to > 36 months in the remaining 55 samples. The
       PCR amplified two regions of pol encompassing the five codons of
       interest which were sequenced. RESULTS: The frequency of at least one
       mutated codon was 41% in ZDV naive patients and 100% after 3 years ZDV
       use. Codon 215 mutation, a high level ZDV resistance mutation, increased
       in prevalence after 24 months of ZDV and was seen in 57% of samples with
       > 36 months ZDV but in only 8% of those with 19-24 months ZDV. (see
       table below) CONCLUSION: Mutation in HIV-1 reverse transcriptase is
       common after ZDV exposure but also occurs in its absence. High level
       resistance mutation (codon 215) is uncommon until more than two years of
       ZDV monotherapy. TABULAR DATA, SEE ABSTRACT VOLUME.
 DE    Amino Acid Sequence/GENETICS  Codon  Drug Resistance, Microbial/GENETICS
       Gene Expression Regulation, Viral/DRUG EFFECTS  Genes, pol/*GENETICS
       Human  HIV Infections/*DRUG THERAPY  HIV-1/*DRUG EFFECTS/GENETICS
       Long-Term Care  Mutation/*DRUG EFFECTS  Polymerase Chain Reaction
       Reverse Transcriptase/ANTAGONISTS & INHIB/GENETICS
       Zidovudine/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).